Prevalence and Correlates of Hepatitis C Viremia Among People With Human Immunodeficiency Virus in the Direct-Acting Antiviral Era
Jimmy Ma(University of Washington), H. Nina Kim(University of Washington), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Christopher B. Hurt(University of North Carolina at Chapel Hill), Joseph A. Delaney(Center for Drug Evaluation and Research), Greer Burkholder, Edward R. Cachay(NorthShore University HealthSystem), Julia Fleming(Fenway Health), Lydia N. Drumright(University of Washington), Geetanjali Chander(Johns Hopkins University), Heidi M. Crane(University of Washington), Rob J. Fredericksen(University of Washington), Sonia Napravnik(University of North Carolina at Chapel Hill), Jeanne Keruly(Johns Hopkins University), Richard D. Moore(Johns Hopkins University), April C. Pettit(Vanderbilt University), Stephanie A. Ruderman(University of Washington), Mari M. Kitahata(University of Washington), Robin M. Nance(University of Washington), Laura Bamford, Audrey R. Lloyd(University of Alabama at Birmingham), Katerina Christopoulos(San Francisco General Hospital), George A. Yendewa(University Hospitals of Cleveland)
Cited by 3
Related Papers
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
|The Journal of Infectious Diseases|1987|1.1k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Self-report measures of medication adherence behavior: recommendations on optimal use
|Translational Behavioral Medicine|2015|832
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694